Hyoscine butylbromide Clinical data Trade names Buscopan, others Other names Butylscopolamine bromide, scopolamine butylbromide Pregnancy category Routes of administration By mouth, rectal, intravenous ATC code Legal status Legal status
Pharmacokinetic data Bioavailability <1% Protein binding Low Elimination half-life 5 hours Excretion Renal (50%) and fecal Identifiers
[7( S)-(1α,2β,4β,5α,7β)]-9-butyl-7-(3-hydroxy- 1-oxo-2-phenylpropoxy)-9-methyl-3-oxa- 9-azonitricyclo[18.104.22.168(2,4)]nonane CAS Number PubChem CID DrugBank ChemSpider UNII ChEMBL ECHA InfoCard 100.005.223 Chemical and physical data Formula C 21 H 30 N O 4 + Molar mass 360.467 g/mol g·mol −1 3D model ( JSmol)
(what is this?) (verify) Hyoscine butylbromide, also known as scopolamine butylbromide and sold under the brandname  Buscopan among others, is a medication used to treat crampy  abdominal pain, esophageal spasms, renal colic, and bladder spasms.  It is also used to improve  respiratory secretions at the end of life. Hyoscine butylbromide can be taken by mouth,  injection into a muscle, or into a vein.
Side effects may include sleepiness, vision changes, dry mouth, rapid heart rate, triggering of
glaucoma, and severe allergies. Sleepiness however, is uncommon.  It is unclear if it is safe in  pregnancy. It appears safe in breastfeeding.  Greater care is recommended in those with heart problems.  It is an  anticholinergic agent, which does not have much effect on the  brain.
Hyoscine butylbromide was patented in 1950 and approved for medical use in 1951.
It is on the  World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not available in the United States,  and a similar compound  methscopolamine may be used instead. The wholesale cost in the  developing world is US$0.004–0.11 per pill as of 2014. It is manufactured from  hyoscine which occurs naturally in the plant deadly nightshade.
A package of injectable buscopan
Hyoscine butylbromide is effective in treating crampy
Hyoscine butylbromide is effective in reducing the duration of the first stage of labour, and it is not associated with any obvious adverse outcomes in mother or neonate.
It is also used during
abdominal or pelvic MRI or CT scans to improve the quality of pictures.
As little of the medication crosses the blood brain barrier it has less effect on the
brain and therefore has reduced occurrence of the centrally-mediated effects (such as delusions, somnolence, and inhibition of motor-functions) which hinder the usefulness of some other anticholinergic drugs. Hyoscine butylbromide is still capable of impacting the  chemoreceptor trigger zone due to the lack of a well-developed blood-brain-barrier in the medulla oblongata, which potentiates the antiemetic effects that it produces via local action on the smooth muscle of the gastrointestinal tract.
It is a
quaternary ammonium compound and a semisynthetic derivative of hyoscine hydrobromide (scopolamine). The attachment of the butyl-bromide moiety effectively prevents the movement of this drug across the blood–brain barrier, effectively minimising undesirable central nervous system side effects associated with scopolamine/hyoscine.
Hyoscine butylbromide is not centrally active and has a low incidence of abuse.
hallucinogen scopolamine.  There have also been reports of abuse in Mashhad Central Prison in Iran. 
In 2015, it was reported that prisoners at Wandsworth Prison and other UK prisons were smoking prescribed hyoscine butylbromide, releasing the potent
Juo, Pei-Show (2001). (2nd ed.). Hoboken: CRC Press. p. 570. Concise Dictionary of Biomedicine and Molecular Biology ISBN . 9781420041309 Archived from the original on 2015-12-08.
^ a b c d
"Buscopan Tablets and Ampoules". Therapeutic Goods Administration, Australia. 8 November 2010. Archived from the original on 30 March 2017 . Retrieved . 22 October 2013
^ a b
"Hyoscine butylbromide SXP". www.ebs.tga.gov.au. 3 July 2017 . Retrieved . 15 March 2018
Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 270. ISBN . 9781284057560
Paice, Judith (2015). . Oxford University Press. p. 43. Care of the Imminently Dying ISBN . 9780190244309 Archived from the original on 2015-12-08.
(3rd ed.). New York: Wiley. 2012. p. 570. Handbook of Palliative Care ISBN . 9781118426814 Archived from the original on 2015-12-08.
"Hyoscine" (PDF). www.kemh.health.wa.gov.au . Retrieved . 11 September 2019
"Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease". www.gov.uk. 20 February 2017 . Retrieved . 15 March 2018 hyoscine butylbromide injection should be used with caution in patients with cardiac disease
^ a b
Hanks, Geoffrey (2011). (4th ed.). Oxford [etc.]: Oxford University Press. p. 805. Oxford textbook of palliative medicine ISBN . 9780199693146 Archived from the original on 2015-12-08.
Fischer, Jnos; Ganellin, C. Robin (2006). . John Wiley & Sons. p. 446. Analogue-based Drug Discovery ISBN . 9783527607495
"WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016 . Retrieved . 8 December 2016
Territo, editor, Dennis A. Casciato ; associate editor, Mary C. (2012). (7th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health. p. 146. Manual of clinical oncology ISBN . 9781451115604 Archived from the original on 2015-12-08. CS1 maint: extra text: authors list ( link)
Satoskar, R. S.; Rege, S. D. Bhandarkar &nirmala N. (1973). . Popular Prakashan. p. 296. Pharmacology and Pharmacotherapeutics ISBN . 9788179915271
"Hyoscine Butylbromide". International Drug Price Indicator Guide. Archived from the original on 10 May 2017 . Retrieved . 4 December 2015
Twycross, Robert (2003). (4th ed.). Oxford: Radcliffe Medical Press. p. 172. Introducing palliative care ISBN . 9781857759150 Archived from the original on 2015-12-08.
Tytgat, G. N. (2007). "Hyoscine Butylbromide: A Review of its Use in the Treatment of Abdominal Cramping and Pain". Drugs. 67 (9): 1343–1357. doi: 10.2165/00003495-200767090-00007. PMID 17547475.
Samuels, L. A.; Christie, L.; Roberts-Gittens, B.; Fletcher, H.; Frederick, J. (2007). "The effect of hyoscine butylbromide on the first stage of labour in term pregnancies". BJOG. 114 (12): 1542–1546. doi: 10.1111/j.1471-0528.2007.01497.x. PMID 17903230.
"Hyoscine butylbromide (Buscopan®)" (PDF). UK: Guy's and St Thomas' NHS Foundation Trust. July 2014. Archived (PDF) from the original on 8 August 2016 . Retrieved . 16 June 2016
Paul Glare, Jeanna Miller, Tanya Nikolova, and Roma Tickoo (12 September 2011). "Treating nausea and vomiting in palliative care: a review". Clinical Interventions in Aging. 6: 243–59. doi: 10.2147/CIA.S13109. PMC . 3180521 PMID 21966219. CS1 maint: multiple names: authors list ( link)
"Medics warned to review Buscopan prescriptions after prisoners found smoking it". Pulse Today . Retrieved . 2018-02-07
Optimisation, NECS Medicines. "Misuse of hyoscine butylbromide (Buscopan)". medicines.necsu.nhs.uk . Retrieved . 2018-02-07
Jalali, Farzad; Afshari, Reza; Babaei, Ali (June 2014). "Smoking crushed hyoscine/scopolamine tablets as drug abuse". Substance Use & Misuse. 49 (7): 793–797. doi: 10.3109/10826084.2014.880178. ISSN 1532-2491. PMID 24494624.